Suppr超能文献

三十年抗逆转录病毒疗法的演进:挑战、成就与未来的前景

The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future.

作者信息

Tseng Alice, Seet Jason, Phillips Elizabeth J

机构信息

University Health Network, Toronto, Ontario, Canada; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.

出版信息

Br J Clin Pharmacol. 2015 Feb;79(2):182-94. doi: 10.1111/bcp.12403.

Abstract

The evolution of human immunodeficiency virus (HIV) treatment has improved our understanding and management of complex pharmacological issues that have driven improved outcomes and quality of life of the HIV-infected patient. These issues include adherence, long- and short-term toxicities, pharmacoenhancement, pharmacogenomics, therapeutic drug monitoring, differential penetration of drugs into sanctuary sites, such as the central nervous system, genital tract and small bowel, and drug-drug and drug-food interactions related to cytochrome P450 drug-metabolizing enzymes, uridine diphosphate glucuronyltransferases and drug transporters, to name a few. There is future promise, as an increased understanding of the immunopathogenesis of HIV and global public health initiatives are driving novel treatment approaches with goals to prevent, control and, ultimately, eradicate HIV.

摘要

人类免疫缺陷病毒(HIV)治疗的发展增进了我们对复杂药理学问题的理解与管理,这些问题推动了HIV感染患者治疗效果的改善和生活质量的提高。这些问题包括依从性、长期和短期毒性、药物增强、药物基因组学、治疗药物监测、药物向中枢神经系统、生殖道和小肠等免疫赦免部位的差异渗透,以及与细胞色素P450药物代谢酶、尿苷二磷酸葡萄糖醛酸转移酶和药物转运体相关的药物相互作用和药物-食物相互作用等等。随着对HIV免疫发病机制的深入了解以及全球公共卫生倡议推动新的治疗方法,目标是预防、控制并最终根除HIV,未来充满希望。

相似文献

3
Pharmacogenetic associations with cytochrome P450 in antiretroviral therapy: what does the future hold?
Expert Opin Drug Metab Toxicol. 2018 Jun;14(6):601-611. doi: 10.1080/17425255.2018.1478964. Epub 2018 May 28.
4
Pharmacogenetics of antiretroviral therapy.
Expert Opin Drug Metab Toxicol. 2014 Aug;10(8):1119-30. doi: 10.1517/17425255.2014.930128. Epub 2014 Jun 18.
5
Drug interactions and antiretroviral drug monitoring.
Curr HIV/AIDS Rep. 2014 Sep;11(3):212-22. doi: 10.1007/s11904-014-0212-1.
6
Pros and cons of therapeutic drug monitoring of antiretroviral agents.
Curr Opin Infect Dis. 2002 Feb;15(1):17-22. doi: 10.1097/00001432-200202000-00004.
7
Pharmacogenomics of CYP3A: considerations for HIV treatment.
Pharmacogenomics. 2009 Aug;10(8):1323-39. doi: 10.2217/pgs.09.53.
8
Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.
Ann Intern Med. 2002 Sep 3;137(5 Pt 2):381-433. doi: 10.7326/0003-4819-137-5_part_2-200209031-00001.
10
Pharmacogenomics of Antiretroviral Drug Metabolism and Transport.
Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:565-585. doi: 10.1146/annurev-pharmtox-021320-111248. Epub 2020 Sep 22.

引用本文的文献

1
MK-8527 is a novel inhibitor of HIV-1 reverse transcriptase translocation with potential for extended-duration dosing.
PLoS Biol. 2025 Aug 26;23(8):e3003308. doi: 10.1371/journal.pbio.3003308. eCollection 2025 Aug.
2
Ethnopharmacological exploration and isolation of HIV-1 latency-reversing agents from Sudanese medicinal plants.
Front Pharmacol. 2025 Aug 6;16:1587128. doi: 10.3389/fphar.2025.1587128. eCollection 2025.
4
HIV-1 Drug Resistance in Children and Implications for Pediatric Treatment Strategies: A Systematic Review and Meta-analysis.
Open Forum Infect Dis. 2025 Jun 26;12(7):ofaf378. doi: 10.1093/ofid/ofaf378. eCollection 2025 Jul.
8
Evaluating the Fiscal Impact of Antiretroviral Therapy for the Management of HIV in the United States 1987-2023.
Clinicoecon Outcomes Res. 2025 May 28;17:407-418. doi: 10.2147/CEOR.S520050. eCollection 2025.
9
Harnessing miRNA dynamics in HIV-1-infected macrophages: Unveiling new targeted therapeutics using systems biology.
Comput Struct Biotechnol J. 2025 May 1;27:1754-1771. doi: 10.1016/j.csbj.2025.04.040. eCollection 2025.

本文引用的文献

4
Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes.
PLoS One. 2014 Jan 31;9(1):e86919. doi: 10.1371/journal.pone.0086919. eCollection 2014.
6
HIV Drug Resistance: Problems and Perspectives.
Infect Dis Rep. 2013 Jun 6;5(Suppl 1):e5. doi: 10.4081/idr.2013.s1.e5.
8
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.
N Engl J Med. 2014 Jan 16;370(3):222-32. doi: 10.1056/NEJMoa1306227.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验